

AGENDA

Uniform Formulary Beneficiary Advisory Panel 24 Sept 2009 @ 8:00 AM

***Naval Heritage Center Theater
701 Pennsylvania Ave. NW., Washington DC 20004***

- **Administrative Meeting (BAP members only @ 7:15 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations of the following drug classes during the Aug 2009 meeting:

- *Drug Class Review: Phosphodiesterase Type 5 Inhibitors (PDE-5 inhibitors) for Erectile Dysfunction*
- *Designated Newly Approved Drugs*
 - *Targeted Immunomodulatory Biologics (TIBs)- Simponi (golimumab)*
 - *Targeted Immunomodulatory Biologics (TIBs)- Cimzia (certolizumab)*
 - *Narcolepsy Drug Class Nasal Allergy Drugs –Nuvigil (armodafinil)*
 - *Alpha-1 blocker BPH Agents - Rapaflo (silodosin):*
- *Changes in prior authorization for Provigil (modafinil)*
- **Formulary status of drugs not in compliance with 32 CFR 199.21(q)(2) (implementing 2008 NDAA Section 703)**
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.